Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals

EMBO Reports

Volumn 14, Issue 2, 2013, Pages 123-128

  Forlini, Cynthia ^a   Hall, Wayne ^b   Maxwell, Bruce ^c   Outram, Simon M ^d   Reiner, Peter B ^e   Repantis, Dimitris ^f   Schermer, Maartje ^g   Racine, Eric ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COGNITION; DRUG RESEARCH; FUNDING; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; PRIORITY JOURNAL;

COGNITION; DRUG EVALUATION, PRECLINICAL; DRUG UTILIZATION; HEALTH; HEALTH BEHAVIOR; HEALTH POLICY; HUMANS; NOOTROPIC AGENTS;

EID: 84873413728     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2012.225     Document Type: Article

References (47)

1. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702-705
2. Hall W (2004) Feeling 'better than well'. EMBO Rep 5: 1105-1109
3. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, Parens E, Sahakian B, Wolpe PR (2004) Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 5: 421-425
4. Larriviere D et al (2009) Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology 73: 1406-1412
5. Bostrom N, Sandberg A (2009) Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics 15: 311-341
6. Repantis D, Laisney O, Heuser I (2010) Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 61: 473-481
7. Repantis D, Schlattmann P, Laisney O, Heuser (2008) Antidepressants for neuroenhancement in healthy individuals: a systematic review. Poiesis Prax 6: 139-174
8. Repantis D Schlattmann P, Laisney O, Heuser (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62: 187-206
9. de Jongh R, Bolt I, Schermer M, Olivier B (2008) Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 32: 760-776
10. Husain M, Mehta MA (2011) Cognitive enhancement by drugs in health and disease. Trends Cogn Sci 15: 28-36
11. Lynch G, Palmer LC, Gall CM (2011) The ikelihood of cognitive enhancement Pharmacol Biochem Behav 99: 116-129
12. Mohamed AD, Sahakian BJ (2011) The ethics of elective psychopharmacology. Int J Neuropsychopharmacol 15: 559-571
13. Smith EM, Farah MJ (2011) Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 137: 717-741
14. Forlini C, Racine E (2009) Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Med Ethics 10: 9
15. Partridge BJ et al (2011) Smart drugs "as common as coffee": media hype about neuroenhancement PLo S ONE 6: e28416
16. Heinz A, Kipke R, Heimann H, Wiesing U (2012) Cognitive neuroenhancement: false assumptions in the ethical debate. J Med Ethics 38: 325-326
17. Mehlman MJ, Berg JW Juengst ET, Kodish E (2011) Ethical and legal issues in enhancement research on human subjects. Camb Q Healthc Ethics 20: 30-45
18. Lucke JC, Bell S, Partridge B, Hall WD (2010) Weak evidence for large claims contribute to the phantom debate. Bio Societies 5: 482-483
19. Racine E, Forlini C (2009) Expectations regarding cognitive enhancement create substantial challenges. J Med Ethics 35: 469-470
20. Juengst E (1998) What does enhancement mean? In Enhancing Human Traits: Ethical and Social Implications (ed Parens E), pp 29-47. Washington, DC, USA: Georgetown University Press
21. Reiner PB (2010) Distinguishing between restoration and enhancement in neuropharmacology. Virtual Mentor 12: 885-888
22. Outram SM (2010) The use of methylphenidate among students: the future of enhancement? J Med Ethics 36: 198-202
23. Teter CJ, Mc Cabe SE, Boyd CJ, Guthrie SK (2003) Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 23: 609-617
24. Teter CJ, Mc Cabe SE, Cranford JA, Boyd CJ, Guthrie SK (2005) Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 53: 253-262
25. Arria AM, Du Pont RL (2010) Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do. J Addict Dis 29: 417-426
26. Farah MJ (2011) Overcorrecting the neuroenhancement discussion. Addiction 106: 1190-1191
27. Maher B (2008) Poll results: look who's doping. Nature 452: 674-675
28. Singh I, Kelleher KJ (2010) Neuroenhancement in young people: proposal for research, policy and clinical management AJOB Neurosci 1: 3-16
29. Larriviere D, Williams MA (2010) Neuroenhancement: wisdom of the masses or "false phronesis"? Clin Pharmacol Ther 88: 459-461
30. Outram SM, Racine E (2011) Developing public health approaches to cognitive enhancement: an analysis of current reports. Public Health Ethics 4: 93-105
31. Banjo OC, Nadler R, Reiner PB (2010) Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLo S ONE 5: e14322
32. Bergström LS, Lynoe N (2008) Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Scand J Public Health 36: 532-537
33. Hotze T, Shah K, Anderson EE, Wynia MK (2011) "Doctor, would you prescribe a pill to help me?" A national survey of physicians on using medicine for human enhancement Am J Bioethics 11: 3-13
34. Boot BP, Partridge B, Hall W (2012) Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 18: 181-184
35. Racine E, Forlini C (2010) Responding to requests from adult patients for neuroenhancements: guidance of the ethics, law and humanities committee. Neurology 74: 1555-1556
36. Moreno JD (2004) DARPA on your mind. Cerebrum 6: 91-99
37. Kirkwood T, Bond J, May C, Mc Keith I, Teh M (2008) Foresight Mental Capital and Wellbeing Project. London, UK: The Government Office for Science
38. Moynihan R, Heath I, Henry D (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324: 886-891
39. President's Commission for the Study of Biomedical Issues (2011) Moral Science: Protecting Participants in Human Subjects Research. Washington DC, USA: President's Commission for the Study of Biomedical Issues
40. Canadian Institutes of Health Research, National Science and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada (2010) Tri-Council Policy Statement: ethical conduct for research involving humans. http://www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS-2- FINAL-Web.pdf
41. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLo S Med 5: e45
42. Sandberg A, Bostrom N (2006) Converging cognitive enhancements. Ann NY Acad Sci 1093: 201-227
43. Beddington J et al (2008) The mental wealth of nations. Nature 455: 1057-1060
44. Savulescu J (2006) Justice, fairness, and enhancement. Ann NY Acad Sci 1093: 321-338
45. Schermer M, Bolt I, de Jongh R, Olivier B (2009) The future of psychopharmacological enhancement: expectations and policies. Neuroethics 2: 75-87
46. Zimmerman E, Racine E (2012) Ethical issues in the translation of social neuroscience: a policy analysis of current guidelines for public dialogue in human research. Account Res 19: 27-46
47. Nadler R, Reiner PB (2010) A call for data to inform discussion on cognitive enhancement Bio Societies 5: 481-482